Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02930889 · ClinicalTrials.gov registry record · NA
Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
A NA study of Benign Prostatic Hyperplasia, sponsored by University of Minnesota.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT02930889 is a NA study of Benign Prostatic Hyperplasia that has completed, run by University of Minnesota. The registered enrollment target is 21 participants, below the 551-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02930889, a NA study of Benign Prostatic Hyperplasia, has completed, sponsored by University of Minnesota.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a investigator-initiated evaluation of the safety and efficacy of treating benign prostatic hyperplasia (BPH) by prostatic artery embolization.
Conditions Studied
Interventions
- DEVICE Prostate Artery Embolization
Study Locations (1)
Minnesota
- University of Minnesota - Minneapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2016-10-01 |
| Est. Completion | 2020-10-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02930889
The ClinicalTrials.gov registry entry for NCT02930889 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 551-participant average among 29 other Benign Prostatic Hyperplasia trials with a reported enrollment target (96% lower). The listed sponsor is University of Minnesota, which has 966 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Benign Prostatic Hyperplasia appearing as the primary indexed condition, and to 1 intervention - of which Prostate Artery Embolization is the first listed.
NCT02930889 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT02930889 about?
NCT02930889 is a clinical study titled "Prostate Artery Embolization (PAE) for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)". This is a investigator-initiated evaluation of the safety and efficacy of treating benign prostatic hyperplasia (BPH) by prostatic artery embolization.
What is the current status of trial NCT02930889?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2016-10-01. Estimated completion is 2020-10-31.
What conditions does trial NCT02930889 study?
This clinical trial studies the following conditions: Benign Prostatic Hyperplasia.
What interventions are being tested in trial NCT02930889?
The interventions under investigation include: Prostate Artery Embolization (DEVICE).
Who is sponsoring clinical trial NCT02930889?
This trial is sponsored by University of Minnesota, which has 966 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02930889 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Benign Prostatic Hyperplasia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ambulatory Long Length URodynamics Evaluation
RECRUITING · NA
-
Safety and Effectiveness of the Optilume® BPH Catheter System in a Post-Market Study
RECRUITING · NA
-
Sacral Neuromodulation for Male Overactive Bladder (MOAB)
RECRUITING · NA
-
A Clinical Study to Evaluate the Safety and Efficacy of the FloStent in Men With Benign Prostatic Hyperplasia Symptoms
RECRUITING · NA
-
5-Alpha Reductase 2 as a Marker of Resistance to 5ARI Therapy
RECRUITING · NA
-
PRescription Exercise for Older Men With Urinary Disease
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.